IMAGE: Bone management for patients undergoing allogeneic stem cell transplant. Figure from from: Kendler DL, Body JJ, Brandi ML, et al. Bone management in hematologic stem cell transplant recipients. Osteoporos… view more
Credit: International Osteoporosis Foundation
Hematopoietic stem cell transplantation (HSCT) is the treatment of choice for many patients with malignant and non-malignant hematological diseases, such as leukemia and multiple myeloma. The success of recent advances in such transplantation techniques and supportive care measures, has led to greater numbers of long-term HSCT survivors.
Consequently, an increasing patient population is impacted by the late effects of HSCT – most notably, bone loss and osteoporosis. The result is an increased risk of fragility fractures causing severe pain, long-term disability and loss of quality of life.
To address this serious problem, the International Osteoporosis Foundation (IOF) expert Working Group on Cancer and Bone Disease has published a new review which looks at the major factors affecting bone health in HSCT patients, and provides expert guidance for the monitoring, evaluation and treatment of bone loss in these patients.
Lead author of the study, Professor David Kendler, of the Department of Medicine, University of British Colombia, Vancouver, Canada, commented:
“Impaired bone health is among
Article originally posted at